Empowering Healthcare Innovation and Economic Growth in Arkansas

Your Gateway to Research, Intellectual Property, and Industry Collaboration

Our Mission

Our mission is to foster commercial investment in the development of inventions, discoveries and other work products flowing from the research at UAMS, the Arkansas Children’s Hospital and the local VA Hospital in order to enhance human healthcare and stimulate economic development in the state of Arkansas. BioVentures’ role is to serve as the nexus for innovation, entrepreneurial educational models, and management of intellectual property and an entry point for industries seeking collaboration.


Our Story

BioVentures was established as a formal outgrowth of the University of Arkansas for Medical Sciences (UAMS) interest in promoting a biomedical technology industry for Arkansas and translating its research into products that benefit human health. UAMS established BioVentures to maximize global, industrial interaction with the University of Arkansas faculty, as well as to facilitate technology transfer, the development of startup companies that are based on technology developed at UAMS, and contributions to Arkansas’ economic development. 

Discovery, innovation, and entrepreneurship are part of our DNA.

Meet the Team

Kevin W. Sexton


Eric Peterson

Executive Vice President

John Sherrill

Technology Manager

Adria Abella

Engineering Team

Rebecca Todd

Grant Writer

Julia Massana


Rob Griffin

VP of Small Business Concerns

Jay Gandy

Entrepreneur in Residence

John Imig

VP Technology Acceleration

Stefanie Kennon-McGill

Program Manager

Michael Geranen

Technology Manager

BioVentures Board

The BioVentures Board comprises a select group of individuals from the realms of business, education, philanthropy and the investment community. The Board advises BioVentures on policies and practices to facilitate basic, medical, clinical and translational research; develop information, products and processes resulting from such research; invest and manage assets to meet priority needs of UAMS and BioVentures.